KAEDI Biotherapeutics

Kaedi Biotherapeutics is a biotechnology company focused on the development of next-generation Adeno-Associated Virus (AAV) gene therapies for rare genetic disorders. The company leverages its proprietary K-AAV platform, which was developed to enhance the safety, efficacy, and tissue-targeting capabilities of viral vectors. Kaedi's primary therapeutic focus includes neuromuscular and central nervous system diseases, with lead programs targeting Pompe disease and Spinal Muscular Atrophy. By optimizing vector design and delivery, the company aims to provide transformative treatments for patients with limited therapeutic options.